Your Directors have pleasure in presenting the Management Discussion and Analysis Report for the year ended on 31st March 2024.
Overview
Vivanza Biosciences Limited is a leading pharmaceutical company in India, committed to delivering high- quality medicines and healthcare solutions. Our core focus areas include research and development, manufacturing, and the distribution of a wide range of pharmaceutical products. This report provides an analysis of the companys performance for the financial year 2023-24, along with insights into the pharmaceutical industry, risk factors, and future outlook.
Industry Overview
The Indian pharmaceutical industry is one of the largest and most advanced among emerging economies. It is known for its robust infrastructure, skilled workforce, and significant export potential. The industry has shown resilience and growth despite global challenges such as supply chain disruptions and regulatory changes. Key drivers include:
Rising Healthcare Demand: Increasing population, higher life expectancy, and a rise in chronic diseases. Government Initiatives: Schemes like Ayushman Bharat and increased public health spending.
Innovation and R&D: Enhanced focus on biotechnology, novel drug delivery systems, and personalized medicine.
Exports: Strong demand for generic medicines in international markets, particularly in the African nation.
Risk Factors Regulatory Risks
The pharmaceutical industry is highly regulated, and changes in policies can impact our operations. We continuously monitor regulatory developments to ensure compliance and mitigate risks.
Market Competition
Intense competition from both domestic and international players poses a challenge. We counter this by focusing on innovation, cost-efficiency, and strategic partnerships.
Global supply chain disruptions, especially for raw materials, can affect production. We have diversified our supplier base and built robust inventory management systems to mitigate this risk.
Currency Fluctuations
As a significant portion of our revenue comes from exports, currency fluctuations can impact profitability. We employ hedging strategies to manage exchange rate risks.
Future Outlook
Looking ahead, Vivanza Biosciences limited aims to maintain its growth trajectory through:
Innovation: Continued investment in R&D for developing cutting-edge therapies.
Global Expansion: Strengthening our presence in existing markets and exploring new geographies. Operational Excellence: Enhancing manufacturing capabilities and adopting advanced technologies. Sustainability: Implementing eco-friendly practices and contributing to community health initiatives.
DISCUSSION ON FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE
In terms of performance, FY 2023-24 has been a reasonable year. Company is focussed on the task on hand in terms of better reliability of operations and more focussed market efforts. Our revenue from operations is Rs. 1446.73 Lakhs. During the FY 2023-24, Company has earned profit of Rs. 42.89 Lakhs.
(Amount in US $)
| Place: Ahmedabad |
| Date: July 05, 2024 |
(Amount in US $)
| Mehta J. A. | Parikh H. A. |
| Managing Director | Director |
| DIN:08210602 | DIN:00027820 |
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
